Emerging Treatments

What treatments are on the horizon for SCN8A?

For years, many of us have been struggling with anti-seizure meds (ASMs) that don’t really help our SCN8A children. They may reduce (or increase) the seizures for a while, but they are drugs that were made with epilepsy more generally in mind, not kids with mutations on their sodium channel.

BUT, there has never been a more exciting time for our community! As of early 2021, there are two compounds in development by two different pharmaceutical companies. We are constantly exploring additional options for treatment, whether they are off-label drugs, research being conducted or discussions with other drug companies.


Neurocrine Biosciences received FDA approval to begin Phase II clinical trials for their drug, NBI-921352 (XEN901) for children and young adults 12-21 years old.

This drug is a selective Nav1.6 sodium channel inhibitor with potential in treating SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE) as well as other forms of epilepsy, including focal epilepsy.

An update on Neurocrine’s SCN8A Program held February 9th, 2021 on the 5th Annual International SCN8A Awareness Day

As mentioned in the video by Carolyn, a document outlining Neurocrine’s epilepsy fact sheet.


Praxis Precision Medicines has recently received rare pediatric disease designation for it’s compound, PRAX-562, for treatment SCN8A-DEE. See the latest community statement we helped them craft to answer YOUR questions below!

A March 2021 Statement released by Praxis to address the concerns and questions of the family you helped us bring to them.